---
title: "Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine | ZBIO Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288488191.md"
description: "Zenas BioPharma announced data from the registrational Phase 3 INDIGO trial of Obexelimab for IgG4-Related Disease. The results were presented at the EULAR 2026 Congress and published in the New England Journal of Medicine."
datetime: "2026-06-02T15:05:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288488191.md)
  - [en](https://longbridge.com/en/news/288488191.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288488191.md)
generator: "portal-rs"
---

# Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine | ZBIO Stock News

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine | ZBIO Stock News

### Related Stocks

- [ZBIO.US](https://longbridge.com/en/quote/ZBIO.US.md)

## Related News & Research

- [Zenas Biopharma posts corporate presentation on autoimmune disease pipeline, led by obexelimab program](https://longbridge.com/en/news/295789100.md)
- [Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership Changes - What's Changed](https://longbridge.com/en/news/295897113.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)
- [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md)
- [The Bull Case For Vertex (VRTX) Could Change Following Upgraded 2026 Guidance And Pipeline Momentum - Learn Why](https://longbridge.com/en/news/296583461.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**